Ventyx Biosciences (NASDAQ:VTYX) Given "Outperform" Rating at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Ventyx Biosciences (NASDAQ:VTYX - Free Report) in a research note issued to investors on Friday morning,Benzinga reports. They currently have a $9.00 target price on the stock, down from their prior target price of $10.00.

A number of other research firms also recently commented on VTYX. HC Wainwright reissued a "neutral" rating and set a $6.00 target price on shares of Ventyx Biosciences in a research report on Tuesday, October 15th. Canaccord Genuity Group lowered their target price on Ventyx Biosciences from $15.00 to $14.00 and set a "buy" rating for the company in a report on Monday, August 12th. Finally, Wells Fargo & Company reduced their price target on Ventyx Biosciences from $16.00 to $11.00 and set an "overweight" rating for the company in a research report on Monday, August 12th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Ventyx Biosciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $9.00.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock traded down $0.04 during trading hours on Friday, hitting $2.20. The company had a trading volume of 886,490 shares, compared to its average volume of 2,055,871. The firm has a market cap of $155.47 million, a P/E ratio of -0.79 and a beta of 0.37. The company has a 50-day moving average price of $2.24 and a two-hundred day moving average price of $2.84. Ventyx Biosciences has a 1 year low of $1.79 and a 1 year high of $11.48.

Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.45) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.12. As a group, equities research analysts anticipate that Ventyx Biosciences will post -2.14 EPS for the current year.

Institutional Investors Weigh In On Ventyx Biosciences

Institutional investors have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. raised its holdings in shares of Ventyx Biosciences by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company's stock worth $30,000 after buying an additional 5,310 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Ventyx Biosciences by 41.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company's stock valued at $56,000 after acquiring an additional 7,096 shares during the period. Norden Group LLC purchased a new stake in Ventyx Biosciences during the 1st quarter valued at about $59,000. Palumbo Wealth Management LLC acquired a new position in shares of Ventyx Biosciences in the third quarter valued at about $26,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Ventyx Biosciences in the first quarter worth about $72,000. Institutional investors and hedge funds own 97.88% of the company's stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.